866-997-4948(US-Canada Toll Free)

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 168 Pages

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) Pipeline Review, H2 2016, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 13, 6, 9 and 2 respectively.Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD).

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10
Therapeutics Development 11
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 13
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 19
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 21
AnGes MG, Inc. 21
AstraZeneca Plc 22
Athera Biotechnologies AB 23
Athersys, Inc. 24
Bayer AG 25
Betagenon AB 26
BiogenCell Ltd. 27
CardioVascular BioTherapeutics, Inc. 28
Celgene Corporation 29
Diffusion Pharmaceuticals Inc 30
Hemostemix Ltd 31
ID Pharma Co., Ltd. 32
Juventas Therapeutics, Inc. 33
LipimetiX Development Inc 34
miRagen Therapeutics, Inc. 35
Nuo Therapeutics, Inc. 36
Proteon Therapeutics, Inc. 37
Recardio GmbH 38
Resverlogix Corp. 39
Sigma-Tau S.p.A. 40
Stemedica Cell Technologies, Inc. 41
Symic Biomedical, Inc. 42
Theravasc, Inc. 43
VESSL Therapeutics Ltd 44
ViroMed Co Ltd 45
Yuyu Pharma, Inc. 46
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
ACP-01 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
AEM-28 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ALD-301 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
alprostadil - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Annexin A-5 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
apabetalone - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
BAY-1193397 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
BC-1 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
beperminogene perplasmid - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
CVBT-141C - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
DVC-10101 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
ELS-140 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
JVS-100 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
levocarnitine propionate hydrochloride - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
MGN-6114 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
MultiGeneAngio - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
O-304 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
PC-mAb - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
PDA-002 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
PF-05285401 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
REC-03 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Rejuveinix - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
rivaroxaban - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
SB-030 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
sodium nitrite SR - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
transcrocetinate sodium - Drug Profile 134
Product Description 134
Mechanism Of Action 134
R&D Progress 134
TXA-127 - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
V-10 - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
VM-202 - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
vonapanitase - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
YY-984 - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
zibotentan - Drug Profile 150
Product Description 150
Mechanism Of Action 150
R&D Progress 150
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 152
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 156
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 157
Featured News & Press Releases 157
Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference 157
Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board 157
Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors 158
Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin 158
Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada 159
Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients 159
Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS 160
Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease 160
May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 161
Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease 162
Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease 162
Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163
Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 164
Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 165
Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 165
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 167
Disclaimer 168

List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H2 2016 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H2 2016 22
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H2 2016 23
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H2 2016 24
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2 2016 25
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2016 26
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd., H2 2016 27
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 28
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H2 2016 29
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 30
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H2 2016 31
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co., Ltd., H2 2016 32
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics, Inc., H2 2016 33
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H2 2016 34
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H2 2016 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H2 2016 36
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H2 2016 37
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2 2016 38
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H2 2016 39
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H2 2016 40
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 41
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H2 2016 42
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H2 2016 43
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H2 2016 44
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H2 2016 45
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2016 152
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H2 2016 153
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H2 2016 154
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H2 2016 155
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2016 156

List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Top 10 Targets, H2 2016 48
Number of Products by Stage and Top 10 Targets, H2 2016 48
Number of Products by Top 10 Mechanism of Actions, H2 2016 50
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50
Number of Products by Top 10 Routes of Administration, H2 2016 52
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 52
Number of Products by Top 10 Molecule Types, H2 2016 54
Number of Products by Stage and Top 10 Molecule Types, H2 2016 54

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *